Hydrophobic cis-platinum complexes efficiently incorporated into liposomes by Khokhar, Abdul R. et al.
United States Patent 15
Khokharet al.
AQAUAUS005117022A
[11] Patent Number: 5,117,022
(45) Date of Patent: * May 26, 1992
 
[54] HYDROPHOBIC CIS-PLATINUM
COMPLEXES EFFICIENTLY
INCORPORATED INTO LIPOSOMES
[75] Inventors: Abdul R. Khokhar; Gabriel
Lopez-Berestein; Roman Perez-Soler,
all of Houston, Tex.
[73] Assignee: The Board of Regents, The University
of Texas System, Austin, Tex.
{*] Notice: The portion of the term of this patent
subsequent to Aug. 20. 2008 has been
disclaimed.
[21] Appl. No.: 234,892
[22] Filed: Aug. 22, 1988
Related U.S. Application Data
[63] |Continuation-in-part of Ser. No. 914.591, Oct. 7, 1986,
which is a continuation-in-part of Ser. No. 788,850.
Oct. 18, 1985, abandoned.
FST} Ent, CLS occ eecceeneeeneeeeneeteneeens CO7F 15/00
(52) US. Cheee 556/137; 424/450;514/492
[58] Field of Search ...............:eecceeee 556/137
[56] References Cited
U.S. PATENT DOCUMENTS
3,904,663 9/1975 Tobecree 556/137 UX
3,993,754 11/1976 Rahman ..... eee 556/137 UX
4.115.418 9/1978 Gale oeeteee §56/137 UX
4.137.248 1/1979 Gale ... . 556/137 UX-_.. §56/137 UX4.140.707 2/1979 Cleare... i
-- §$6/137 UX4,169,846 10/1979 Kidani...
  
  
4.203.912 5/1980 Hydes... ..- 556/137 UX
4,225,529 9/1980 Hydes........... we. 556/137 UX
4,230,063 10/1980 Hydes «1... 556/137 UX
4,235,871 11/1980 Papahadjopoulos........ 556/137 UX
4,241,046 12/1980 Papahadjopoulos........ 556/137 UX
4,256,652 3/198] Kidani «eee 556/137 UX
4,271,085 6/1981 Amundsen..........-0 556/137 UX
4,330,534 5/1982 Sakurai ..... 556/137 UX
4.431.066 2/1984 Bulten 0... eee 556/137 UX
4.466.924 8/1984 Verbeek «0.0...eee 556/137 UX
4,522,803 6/1985 Lenk oo... eceeeereeteees 556/137 UX
4,657,927 4/1987 Cleare ...... cerns §56/137 UX
4,661,516 4/1987 Brown .......eee 556/137 UX
4,663,167 5/1987 Lopez-Berestein . 556/137 UX
4,680,308 7/1987 Schwartz «ee 556/137 UX
4,760,155 7/1988 Heffernan ...........-0+ 556/137 UX
4,760,156 7/1988 Heffernan.... , 556/137 UX
4,760,157 7/1988 Child «0...eeeeeeeerseeneeee 556/137 UX
FOREIGN PATENT DOCUMENTS
§$69425 12/1985 Australia ......ccreseeeeneere §56/137
(List continued on next page.)
OTHER PUBLICATIONS
Schwartz et al,
61:1519-1525 (1977).
Cancer Treatment Reports,
(List continued on next page.)
Primary Examiner—Paul F. Shaver
Attorney, Agent, or Firm—Arnold, White & Durkee
[57] ABSTRACT
The present invention concerns a platinum (II) four-
coordinant complex having the formula:
R2
Ri—Pull)\R3
wherein Ry is an alkyl diamine or cycloalkyl diamine
and R2and R3are an alkylcarboxylato containing from
five to ten carbon atoms. The Ry is preferably trans-
D.L-1,2-diaminocyclohexane, trans-R.R-1,2-
diaminocyclohexane, _trans-S,S-1,2-diaminocyclohex-
ane, cis-1,2-diaminocyclohexane ethylene diamine or
1,1-bis(aminomethyl)cyclohexane. The R2 and R3 are
preferably neohexanoato, neoheptanoato,
neononanoato, neodecanoato, neooctanoato, neopen-
tanoato, 2-ethylhexanoato, 2-ehtylbutyrato, 2-propyl-
propanoato, 2-methyl-2-ethylheptanoato, 2,2-diethyl-
hexanoato, 2,2-dimethyl-4-ethylhexanoato, 2,2-diethyl-
4-methylpentanoato, 2,2-dimethyloctanoato, 2-methyl-
2-ethylheptanoato, 2,2-diethylhexanoato, 2,2-diethy]l-4-
methylpentanoato or 2,2,4,4-tetramethylpentanoato.
In an important further aspect, the present invention
involves preparation and therapeutic use of a liposome
comprising a phospholipid and a four-coordinate plati-
num complex having the formula:
R2yy
R)—Pui)\ R3
wherein Ryis an alkyl diamine or cycloalkyl diamine
and R2 and R3are an alkylcarboxylato containing from
about five to about fourteen carbon atoms. The Ri, R2
and R3 functions are preferably as described above with
the exception that R2 and Ramay have even longer alkyl
chains such as myristate and laurate,i.e., up to fourteen
carbon atoms. For therapeutic use, a pharmaceutical
composition comprising this liposome and a pharma-
ceutically acceptable carrier or diluent maybereadily
prepared by methods well knownto those skilled in the
art. The liposomes are useful vehicles for solubilizing
the otherwise aqueously insoluble complexes of the
present invention. The phospholipids of the liposomes
may be one or more of phosphatidylglycerol, phos-
phatidylcholine, sphingomyelin, phosphatidic acid or
phosphatidylserine. The liposomes more preferably
consist essentially of phosphatidylglycerol, phos-
phatidylcholine or a combination thereof and may also
comprise cholesterol. The liposomesofthe present most
preferably comprise phospholipid consisting essentially
of dimyristoyiphosphatidylglycerol, dimyristoylphos-
phatidylcholine or a’ combination thereof.
28 Claims, No Drawings
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HYDROPHOBIC CIS-PLATINUM COMPLEXES
EFFICIENTLY INCORPORATED INTO
LIPOSOMES
This is a continuation-in-part of U.S. patent applica-
tion Ser. No. 914,591 Oct. 7, 1986, which was a continu-
ation in part of U.S. patent application Ser. No. 788,850,
filed Oct. 18, 1985, now abandoned, both of which are
incorporated byreference herein.
BACKGROUNDOF THE INVENTION
This invention relates to newly synthesized platinum
complexes with hydrophobic properties. The use of
liposomesincorporating these newand previously syn-
thesized complexes in anti-tumor chemotherapyis also
described.
Cis-platinum (CDDP)is a highlyeffective drug in the
treatment of several neoplastic diseases in humans (Lo-
ehrer et al. (1984) Ann. Int. Med. V 100, pp 704-713).
However.its use is limited by severe systemic toxicity,
particularly nephrotoxicity and neurotoxicity (Zwelling
et al. Platinum Complexes. In: Pharmacologic princi-
ples of cancer treatment (1982) Ed by B. A. Chabner.
Saunders, Philadelphia, Pa.). In an attempt to modify
the therapeutic index of CDDP. newderivatives have
been synthesized during the last decade. However, the
sdevelopment of some promising analogues has been
prevented by their low hydrosolubility, which de-
creases their potential for clinical use (Burchenalet al.
(1979) Cancer Treat. Rep. V 63, pp 1493-1497).
Liposomesare lipid vesicles which mayform sponta-
neously upon addition of an aqueous solution to a dry
lipid film (Mayhewet al., In: Liposomes (1983) Ed by
Marc J. Ostro, Marcel Dekker, Inc., New York. N.Y.).
Liposomes maybe used as drug carriers of hydrophobic
or hydrophilic drugs entrapped in their hydrophobic or
hydrophilic compartments respectively. Multilamellar
liposomes are multilayer lipid vesicles (MLV) that are
particularly suited for carrying hydrophobic drugs
since their hydrophobic compartment is larger than
their hydrophilic compartment. Wheninjected intrave-
nously (iv) in animals, (Kasi et al. (1984) Int. J. Nucl.
Med. Biol. V 11 pp 35-37, Lopez-Berestein et al.
«1)(1984) Cancer Drug Deliv. V 1, pp 199-205) and
humans (Lopez-Berestein et al. (2)(1984), Cancer Res.
V44, pp 375-378), MLV concentratein the liver, spleen
and otherorgansrich in reticuloendothelial (RES)cells.
Liposomes have been previously used in vitro to
deliver chemotherapeutic agents, (Mayhewetal., Lipo-
somes (1983), ed. by Ostro, Marcel Dekker, Inc., New
York, N.Y.) and immunomodulators and anti-fungal
agents in vitro (Mehtaetal. (1984), Immunology V 51
pp 517-527, and in vivo in animals (Lopez-Berestein et
al. (4)(1984) Clin Exp Metastasis V 2 pp 127-137 and
Lopez-Berestein et al. (1983), J Inf Dis V 147, pp
937-945) and in humans (Lopez-Beresteinet al. (1985)J.
Inf. Dis. V 151 pp 704-710).
Recent studies showthat liposomes can reduce cer-
tain types of drug-related toxicities such as doxorubicin
cardiotoxicity (Forssen et al. (1981) Proc. Natl. Acad.
Sci. V 78 pp 1873-1877, Olson et al. (1982), Eur. J.
Cancer Clin..Oncol. V 18 pp 167-176, Gabizonet al.
(1982) Cancer Res. V 42 pp 4734-4739, Hermanetal.
(1983) Cancer Res. V 43 pp 5427-5432) and CDDP
nephrotoxicity, (Freise et al. (1982), Arch. Int. Phar-
macodynamie Therapie V 258 pp 180-192) and may
increase antitumoractivity as a result of a slowrelease
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mechanism (Mayhewetal. (1978) Ann. N.Y. Acad.Sci.
V 308. pp 371-386, Patel et al. (1984) Int. J. Cancer V 34
pp 717-723) a higher drug uptake by tumorcells or due
to a moreselective organ distribution (Gabizon etal.
(1983) Cancer Res. V 43, pp 4730-4735 and Mayhewet
al. (1983), Cancer Drug Deliv. V 1 pp 43-58). In U.S.
Patent No. 4,330,534 N+-acylcytosine arabinoside incor-
porated into liposomes, for example, was found to be
therapeutically effective when administered to tumor-
bearing animals. In spite of these promising results, the
clinical application of antitumor agents encapsulated in
liposomes has been delayed, mainly due to formulation,
drug stability and large scale production problems.
CDDPhasbeen previously encapsulated in MLVbut
with a very lowencapsulation efficiency (7.4%) and
poorstability (75% at 48 hours in 0.9% NaCl solution)
(Freise et al. (1982) Arch. Int. Pharmacodynamie Ther-
apie V 258 pp 180-192).
In U.S. Pat. No. 4,256,652 are described certain plati-
num compounds comprising resolved stereoisomers of
1,2 diaminocyclohexane (DACH). The isomersutilized
were cis-DACH, trans-RR-1,2-DACH and trans-SS-
1,2-DACH.The platinum compoundsdescribed therein
contained, in addition to a resolved DACHisomer, two
hydrophilic platinum ligands such as bromide, iodide,
nitrate, bromoacetate, sulfate or glucuronate. Theplati-
num compounds-comprising the trans-RR-1,2-DACH
were described as often more therapeutically effective
than those bearing cis-DACH.
In European Patent Application No. 83306726.7 cer-
tain platinum compounds are described which may
comprise diaminocyclohexane (non-stereochemically
resolved) and do comprise phosphatidyl groups having
fatty acid substituents. These compoundsare described
as largely insoluble in plasma and preferably employed
with lipid vesicle carriers The platinum compound-
phospholipid vesicles were preferably prepared bya
sonic oscillation procedure which characteristically
yields unilamellar vesicles.
SUMMARYOF THE INVENTION
Thepresent invention concernsa platinum (II) four-
coordinant complex having the formula:
R2ye
RiPull)\ R3
wherein R, is an alkyl diamine or cycloalkyl diamine
and R2 and R3are an alkylcarboxylato containing from
five to ten carbon atoms. The R, is preferably trans-
D,L-1,2-diaminocyclohexane; trans-R,R-1,2-
diaminocyclohexane, _trans-S,S-1,2-diaminocyclohex-
ane, cis-1,2-diaminocyclohexane ethylene diamine or
1,1-bis(aminomethyl)cyclohexane. The R2 and R3 are
preferably neohexanoato, neoheptanoato,
neononanoato, neodecanoato, neooctanoato, neopen-
tanoato, 2-ethylhexanoato, 2-ethylbutyrato, 2-propyl-
propanoato, 2-methyl-2-ethylheptanoato, 2,2-diethyl-
hexanoato, 2,2-dimethyl-4-ethylhexanoato, 2,2-diethyl-
4-methylpentanoato, 2,2-dimethyloctanoato, 2-methy]l-
2-ethylheptanoato, 2,2-diethylhexanoato, 2,2-diethyl-4-
methylpentanoato or 2,2,4,4-tetramethylpentanoato.
In an important further aspect, the present invention
involves preparation and therapeutic use of a liposome
comprising a phospholipid and a four-coordinateplati-
num complex having the formula:
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R:>ye
RiPui
Rs
wherein R; is an alkyl diamine or cycloalky] diamine
and R: and R3; are an alkylcarboxylato containing from
about five to about fourteen carbon atoms. The Rj. R2
and R;functions are preferably as described above with
the exception that R2 and R3 may have even longer
alky] chains such as myristate and laurate, i.e., up to
fourteen carbon atoms. For therapeutic use, a pharma-
ceutical composition comprising this liposome and a
pharmaceutically acceptable carrier or diluent may be
readily prepared by methods well known to those
skilled in the art. The liposomes are useful vehicles for
solubilizing the otherwise aqueously insoluble com-
plexes of the present invention. The phospholipids of
the liposomes may be one or more of phosphatidy-
glycerol, phosphatidylcholine. sphingomyelin, phos-
phatidic acid or phosphatidylserine. The liposomes
more preferably consist essentially of phosphatidyl-
glycerol. phosphatidylcholine or a combination thereof
and may also comprise cholesterol. The liposomes of
the present most preferably comprise phospholipid con-
sisting essentially of dimyristoylphosphatidylglycerol.
dimyristoylphosphatidylcholine or a combination
thereof.
In one preferred aspect. the liposomesof the present
invention comprise phospholipid consisting essentially 3
of dimyristoy]phosphatidylglycerol and dimyristoy]-
phosphatidylcholine in a ratio between about I to 10
and about 1010 1. more preferablyin a ratio of about 3
to 7. These liposomes generally contain the platinum
complex and the phaspholipid in a ratio between about
1 to 10 and about 1 to 30. more preferablyin a ratio of
about 1 to 15. The liposomesofof the present invention
are preferably multilamellar to enhance encapsulation
of the largely hydrophobic platinum complexes.
A significant aspect of the present invention involves
a methodoftreating an animal afflicted with tumorcells
sensitive to a platinum (II) four-coordinate complex.
This method comprises administering a liposome to the
animal, said liposome comprising a phospholipid and a
platinum (II) four-coordinant complex having the for-
mula:
R>
4
Ry,Pu)\R3
wherein Rj) is an alky!] diamine or cycloalkyl diamine
and R2and R3are an alkylcarboxylato containing from
five to fourteen carbon atoms. The various R groups are
variable as defined above. The step for administering
the lipoosomal platinum (II) complex of the present
invention to a tumor-bearing animal is most commonly
intravenous injection, intraarterial injection, intramus-
cular injection, intraperitoneal injection, intrathecal
injection, subcutaneousinjection, intrapleural injection,
topical application or oral dosage. As is the case for
most chemotherapy, the administering step is repeated
on a timed schedule. To optimize therapeutic effective-
ness of the present chemotherapeutic method for inhib-
iting growth of tumors in a host, a patient bearing a
tumor type generally acknowledged to contain cells
whose growth is inhibited by platinum (II) complexes
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should be selected and administering the platinum (II)
four coordinate complex of claim 1, 2 or 3 to said host.
This platinum (II) four coordinate is most preferably in
liposomal form as described above but may be other-
wise used if applicable.
DETAILED DESCRIPTION OF PREFERRED
EMBODIMENTS
Platinum (II) four-coordinate complexes were pre-
pared utilizing a variety of carboxylato ligands in com-
bination with amino or diaminoligands. Certain of these
complexes, either totally new or newas included in
liposomes, were, after encapsulation in liposomes,
found to be effective in vitro toxins for cancerouscells.
In a general sense. the square-planar platinum (II)
four coordinate complexes of the present invention
have the formula:
where R2 and R3 are preferably carboxylato monoan-
ions bearing a hydrophobic radical function. Addition-
ally. Ry is preferably a vicina] diaminoalkane or vicinal
diaminocycloalkane. It is contemplated that, under
somecircumstances, Rj may be composed of two inde-
pendent alkylamines, cycloalkylamines or ammonia
although such monoanions have thusfar beenless effec-
tive. These components confer upon the complex a
substantial solubility (normally greater than about 5.0
mg/ml) in methanol or chloroform at ambient tempera-
tures and a substantial insolubility (less than about 0.5
mg/ml) in aqueous solutions at ambient temperatures.
R3 is most preferably trans-SS-1,2-diaminocyclohex-
ane trans-RR-1,2-diaminocyclohexane, or  cis-1,2-
diaminocyclohexane.
The hydrophobic radical function, that function co-
valently pendant from the carboxyl group or from an
intermediate or linking group, maybe an alkyl, substi-
tuted aryl, aryl, alkenyl], cycloalkyl or cycloalkenyl
group or even combinations of these functions such as
alkylaryl or arylalkenyl, to name but two of the many
possible hydrophobic combinations. The hydrophobic
radical function characteristically has between 5 and 20
carbon atoms. Whenthis hydrophobic radical function
comprises an alkyl! or alkenyl! group, this group may be
straight or branched. Polar functions such as hydroxyl
groups, for example, substituted on the hydrophobic
radicals would tend to lessen their hydrophobicity and
mayrender them less useful for the purposes of the
present invention.
Liposomes containing the platinum (II) complexes
described herein may be prepared from various am-
phipathic substances including natural or synthetic
phospholipids. The phospholipids usable to produce
liposomes are numerous and not exhaustively listed
herein since they are generally well known in theart.
These phospholipids include but are not limited to:
lecithin, phosphatidylethanolamine, lysolecithin, lyso-
phatidylethanolamine, |phosphatidylserine, —_phos-
phatidylinositol, sphingomyelin, cardiolipin, phospha-
tidic acid and the cerebrosides. Most preferable phos-
pholipids for the practice of aspects of the present in-
vention include dimyristoylphosphatidylglycerol
(DMPG) and dimyristoylphosphatidylcholine
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(DMPC). Cholesterol in minor proportions ranging
from less than 1% to about 50% maybe included with
phospholipids and platinum (IT) complexes to produce
liposomesofthe present invention. A preferable but not
limiting combination of DMPG and DMPC has been
found to be a ratio of 3 to 7 although ratios between 1:10
and 10:1 are contemplated as satisfactory. Ratios of
platinum (II) complex to phospholipid between about 1
to 10 and about 1 to 30 are contemplated as generally
satisfactory although a 1] to 15 ratio was primarily used
in studies thus far.
Either unilamellar or multilamellar or other platinum
(IT) complex - containing liposomes maybe used in the
practice of the present invention. Multilamellar lipo-
somes are presently preferred since the platinum (1)
complexes of the present invention are substantially
water - insoluble and they appear to be incorporated
into the phospholipid bilayers of the liposome lamellae.
A procedure for synthesis of the platinum HI com-
poundsof the present invention may be generally de-
scribed. Methods for producing the complexes of the
present invention can involve various pathways and
intermediates. One pathwayinvolves theutilization of a
diiodo (cycloalkyldiamine) platinum (II) complex.
Such diiodo (cycloalkyldiamine) platinum (IT) inter-
mediates may be made,for example. byinitially combin-
ing potassium iodide (e.g.. 8 moles, 6.4 molar in water)
with potassium tetracloroplatinum (II) (e.g., 1 mole, 0.2
molar in water). This combination results in the forma-
tion of 1 mole of potassium tetraiiodoplatinum (II).
The tetratiodoplatinum (11) compound is combined
with an equimolar amount of cycloalkyldiamine and
stirred for about one hour at ambient temperature. A
precipitate forms and maybe washed with water, etha-
nol and ether successively, prior to drying. This proce-
dure gives about an 86% yield of diiodo (cycloalkyldia-
mine) platinum (11).
Example I. shownlater herein, specifically shows the
preparation of diiodo (trans-R,R-1,2-diaminocyclohex-
ane) platinum (I).
Another intermediate which may be useable for the
preparation of the complexes of the present inventionis
a sulfato (cycloalkyldiamine) platinum (II). For prepa-
ration of this compound the diiodo(cycloalkyldiamine)
platinum (1) compound described above is mixed with
about an equimolar amountof silver sulfate and water.
After stirring overnight (protected from light), silver
iodide precipitates and maybe separated byfiltration.
The filtrate may then be evaporated to dryness to give
a yellowproduct, i.e. sulfato (cycloalkyldiamine) plati-
num II complex, in a yield as high as 95% or greater.
Forcertain routes of platinum complex preparation, a
silver carboxylato salt is a preferred intermediate. Such
a silver carboxylato salt may be prepared by adding an
equimolar amountof silver nitrate (1.25 molar) to a
sodium carboxylato salt (0.38 molar) both in water.
After stirring at room temperature for about | hour
(protected from light) the product silver carboxylato
salt precipitates in high yield and may be washed with
water and dried.
Four exemplary synthetic routes utilizing the above
intermediates may be readily described leading to the
complexes of the present invention.
Synthetic route #1 involves, for example, the reac-
tion of 1 mole of diiodo(cycloalkyldiamine)platinum
(I) with 2 moles of a silver carboxylato salt (0.2 molar
in chloroform). After mixing these ingredients, the mix-
ture should be stirred overnight at room temperature
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and precipitated silver iodide separated byfiltration.
The filtrate should contain the product cis dicarbox-
ylato (diaminoalkyl) platinum H in high yield.
Synthetic route #2 involves. for example, the reac-
tion of a sulfato(cycloalkyldiamine)platinum HH com-
pound (1 mole, 0.08 molar and water with sodium car-
boxylato salt (4 moles, 0.07 molar in aqueous ethanol
5:1) such a mixture should bestirred for at least about 2
hours and should result in gummy material which may
be extracted with chloroform and dried to give the
product cis carboxylato(cycloalkyldiamine)platinum
(IJ) complex.
Synthetic route #3 involves, for example, the reac-
tion of sulfato(cycloalkyldiamine)platinum (IT) (1 mole,
0.05 molar in water) mixed with a barium carboxylato
salt solution prepared bythe reaction of bariurn hydrox-
ide and carboxylato acid in water so that 2 moles of
e-carboxylato compoundare present. After stirring for
three days a precipitate was noted andthe final product
was extracted in chloraform and dried. The result was
the cis carboxylato(cycloalkyldiamine)platinum II com-
plex.
Synthetic route #4 involves the reaction of about 80
mmole potassium iodide with about 10 mmole potas-
sium tetrachloroplatinate (IJ) in, e.g., 300 ml water are
allowed to react to form a dark brown solution and a
solution of 1,1!-bis(aminomethyl)cyclohexane dihydro-
chloride and alkali metal hydroxide (20 mmole) in about
30 ml water added dropwise. After stirring at room
temperature for about one hour, a precipated product
(cis-diiodo[1,1-bis(aminomethyl)cyclohexane platinum
(ii) is separated out, for example byfiltration, and dried.
The product is then reacted with a silver carboxylato
salt in a 1:2 molar ratio in chloroform for about 20 hr
(protected from light) and precipitated silver iodide
separated byfiltration. The filtrate is then evaporated to
give alight yellow product which mayberecrystallized
from acetone to give white crystals.
Synthetic routes 1, 2, 3 and 4 are minor synthetic
variations and give rise to the same type of platinum
complexes while utilizing slightly different chemical
routes.
The methods of preparation of particular platinum
(11) complexes and chemotherapeutic treatment with
particular platinum (11) complexes described in the Ex-
amples contained later herein are readily adapted to the
production’ and use of analogously described and
claimed complexes bysimple substitutions, for example,
of appropriate vicinal diamines or hydrophobic radical-
containing carboxylato monoanions. The complexes of
the present invention which were specifically synthe-
sized and tested are shown in Table ] with the exception °
of complexes 4 and 5 all of these complexes are newly
synthesized and none have before been included in
liposomes.
TABLE1
PLATINUM COMPLEXES
Complex # Complea Name
 
1. cis-bis-Neohexanoato (trans-R,R-1,2-DACH*)
platinum (11).H2O
2. cis-bis-Neoheptanoato (trans-R,R-S,S-1,2-DACH)
platinum (11)
3. cis-bis-Neononanoato (trans-R,R-S,S-1,2-DACH)
platinum (II)
4. cis-bis-Laurato (trans-R.R-S.S-1,2-DACH)
platinum (11)
5. cis-bis-Myristato (trans-R.R-S.S-1,2-DACH)
platinum (II)
6. cis-bis-Neohexanoato [1,!-bis
5,117,022
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TABLE 1-continued
 
PLATINUM COMPLEXES
Complex # Complea Name
(aminomethyl eyclohexane) platinum (11)
7. cis-bis-Neodecanoato [1.]-bis
(aminomethyl)cyclohexane] platinum (11)
8. cis-bis-Neoheptanoato (trans-R.R-1.2-DACH)
platinum (ID)
9. cis-bis-Neoheptanoato [1.1-bis
(aminomethy])cyclohesane} platinum (1)
10. cis-bis-2,2-dimethyloctanoato (trans-R.R-1,2-
DACH) platinum (IF)
11. cis-bis-Neononanoato (trans-R.R-1.2-DACH)
platinum (IF)
12. cis-bis-Neoheptanoata (ethylenediamine) platinum
(Hy)
13. cis-bis-Neopentanoato [1.]-bis
{aminomethylcycloheaane] platinum (1)
14. cis-bis-Neononanoato [].1-bis
{aminomethyl)cycloheaane] platinum (11)
4S. cis-bis-2-ethylheaanoato (trans-R.R-S.S-1.2-
DACH) platinum (1).H20
16. cis-bis-ethylbutyrato (trans-R,R-S,S-1,2-DACH)
platinum (11).H2O
tT. cis-bis-propy Ipentanaato (trans-R.R-S.S-1.2-
DACH) platinum (11).H20
TS. cis-bis-2-methyl-2-ethylheptanoato (trans-R.R-
1.2-DACH) platinum (11)
19. cis-bis-2.2-diethy lhexanoato (trans-R.R-1.2-
DACH) platinum (1)
20. cis-bis-2,2-dimethy]-4-ethylheaanoato (trans-
R.R-1.2-DACH) platinum (1)
21. cis-bis-2.2-diethyl-4-methylpentanoato (trans-
R.R-1.2-DACH) platinum (1h)
cis-bis-2.2-dimethyloctanoato(trans-§,S-1.2-
DACH) platinum (1}}
23. cis-bis-2-methyl-2-ethyTheptanoato (trans-S.S-
1.2-DACH) platinum (11)
 
24. cis-bis-2.2-diethylheaanoato (trans-S.$-1.2-
DACH}) platinum (11)
25. cis-bis-2,2-diethy]-4-methylpentanoato (trans-
§.8-1,2-DACH) platinum(ID)
26. cis-bis-2,2.4.4-tetramethylpentanoato (trans-
R.R-1.2-DACH) platinum (II)
27. cis-bis-neodecanoato (cis-1.2-DACH Platinum (II)
*DACH = 1.2 diamimocycloheaane
It is understood that the methods of the present in-
vention include platinum complexes synthesized with
analkyl or cycloalky! diamine and any of numerous
alkyl acids with hydrophobic pendant alkyl chains.
These alky! acids include positional isomers of neodeca-
noic acid not specifically used thusfar. These positional
isomers include:
2,2,5-Trimethylheptanoic acid;
2.2,6-Trimethylheptanoic acid;
2,2,4-Trimethylheptanoic acid;
2.2,3-Trimethylheptanoic acid;
2,2,3,5-Tetramethylhexanoic acid;
2,2,4,5-Tetramethylhexanoic acid;
2,2,3,3-Tetramethylhexanoic acid;
2,2,4,4-Tetramethylhexanoic acid;
2,2,5,5-Tetramethylhexanoic acid;
2,2-Dimethy1!-3-Ethylthexanoic acid;
2-Ethy!-2,5-Dimethythexanoic acid;
2-Ethy1]-2,4-Dimethylhexanoic acid;
2-Ethy!-2,3-Dimethylhexanoic acid;
2-Ethy1-2,3,4-Trimethylpentanoic acid;
2,3-Diethy]l-2-Methylpentanoic acid;
2,2-Diethyl-3-Methylpentanoic acid;
2,2-Diethy]-3,3-Dimethylbutanoic acid;
2,3-Diethyl-2,3-Dimethylbutanoic acid; and
wn
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2-Ethyl-2.4,4-Trimethylpentanoic acid.
Liposomes comprising phospholipids and platinum
complexes (Pt-liposomes) of the present invention are
useful in inhibiting both the growth and metastatic
spread of tumors.
Such Pt-liposomes maybe administered parenterally,
topically or orally. Oral or parenteral dosages of these
Pt-liposomes between about 2.5 mg/kg body weight
and 25 mg/kg body weight are contemplated as ade-
quate in most conditions. The particular dosages, if a
tumor-bearing humanis being treated, mayvaryin each
case according to the condition of the patient, the type
and extent of tumor, and particular Pt-liposome toxic-
ity.
The amount of liposomal-platinum included in the
pharmaceutical composition and the dosage utilized in
the method of treatment of the invention will vary de-
pending in each case upon the conditions ofthe patients,
the nature of the tumor undergoing treatment, antitu-
mor activity of liposomal-platinum, the toxicity and
solubility characteristics thereof, etc. Liposomal-
platinum mayalso be administered in combination with
other antitumor agents in a combined therapeutic regi-
men.
Parenteral administration may be intraperitoneal,
subcutaneous, intrapleural, intrathecal, intraurethral,
intravenous, intraarterial, intramuscular or intralym-
phatic. Such parenteral administration preferably in-
volves Pt-liposome suspensions in pharmaceutically
acceptable solutions such as sterile isotonic aqueous
solutions. These suspensions maybe obtained fully pre-
pared or maybe prepared from preformed components.
As knownto those skilled in the art, Pt-liposomes may
be prepared as pellets or powders. These pellets or
powders may be mixed with pharmaceutically accept-
able solutions to form suspensions for parenteral admin-
istration.
Topical administration of Pt-liposomes mayinvolve
pharmaceutical compositions such as suspensions,
creams or ointments which maybe obtained fully pre-
pared or prepared from Pt-liposome powdersorpellets.
Such topical administration maybe nearto sites of can-
cerous lesions such as the epithelium or mucosa for
example.
Oral administrations of Pt-liposomes preferably in-
volve encapsulation of Pt-liposome powderor pellets
whereby the Pt-liposomes are protected from much
gastric and intestinal digestive activity before release
from the encapsulation.
Whendesired, Pt-liposomes may be prepared to con-
tain, for example, other therapeutic agents for treatment
of tumors or anti-oxidants to aid in liposomestabiliza-
tion.
Use of the complexes of the present invention, partic-
ularly as a componentof liposomes, focuses upon the
inhibition of tumor growth and prevention of the meta-
static spread of tumors. For example, first a host is
identified as bearing a tumor type known to generally
contain cells whose growth is often inhibited by plati-
num (II) complexes. Tumor growth in the host may be
inhibited by administering to the host the Pt-containing
liposomesof the present invention.
Similarly, the metastatic spread of tumors in a host
maybe inhibited. A host bearing metastatic or poten-
tially metastatic tumors of a type noted often to be
sensitive to platinum (II) complexes, would first be
identified. The administration of the Pt-containing lipo-
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somes of the present invention to that host would serve
to inhibit metastatic spread.
The following examples are presented to further illus-
trate preferred embodiments of the present invention:
theyare not intended to limit the invention unless other-
wise so stated in the accompanying claims.
EXAMPLE|
MATERIALS AND ANALYSES
K>P1Cly was purchased from AESAR (Johnson Mat-
they, Inc. Seabrook, N.H.). 1.2-diaminocyclohexane
(DACH) was purchased from the Aldrich Chemical
Co., Milwaukee, Wis. trans-RR-1,2-DACH and trans-
SS-1.2-DACH from Morton Thiokol, Inc.. Danvers,
Mo., cis-1,2-diaminocyclohexane from Turner Labs,
Woodland, Tex. and neodecanoic acid from Exxon
Chemical Co., Houston, Tex. Elemental analyses of the
platinum complexes were performed by Robertson
Laboratory, Inc., Madison, N.J. The Liposome Co.,
Princeton, N.J. synthesized and provided isomerically
pure: 2,2-dimethyloctanoic acid: 2,2-dimethy]l-4-ethyl-
hexanoic acid: 2-ethyl-2-methylhexanoic acid; 2,2-die-
thylhexanoic acid: and 2,2-diethyl-4-methylpentanoic
acid. Other alkyl acids and reagents were obtained from
common commercial sources such as the Exxon Chemi-
cal Co.
EXAMPLE2
THE PREPARATION OF DIIODO
(TRANS-R,R-1,2-DIAMINOCYCLOHEXANE)
PLATINUM(ID
A solution of potassium iodide (53 g. 0.32 mol.) in 50
ml. of water was added to an aqueousfiltered solution
of potassium tetrachloroplatinum (11) (16.6 g, 0.04 mol.)
in 200 ml. of water. Trans-R,R-1,2-diaminocyclohexane
(4.56 g. 0.04 mol.} was added to the potassium tetraiodo-
platinum (II) solution. The mixture was kept stirring for
one hour at room temperature. The yellow product
separated out. which wascollected on the filter, washed
repeatedly with water, ethanol, either and finally dried
under vacuum. Yield (86%).
EXAMPLE3
THE PREPARATION OF SULFATO
(TRANS-R,R-I,2-DIAMINOCYCLOHEXANE)
PLATINUM(II)
Diiodo (trans-R,R-1,2-diaminocyclohexane) platinum
(II) (16.88 g, 0.03 mol.) was added to a solution ofsilver
sulfate (8.88 g. 0.0285 mol.) in water. The mixture was
left stirring overnight at room temperature (protected
from light). Silver iodide was separated byfiltration and
the filtrate was evaporated to dryness under reduced
pressure to give a yellow product. The final product
was purified from water. Yield (95%).
EXAMPLE4
THE PREPARATIONOF SILVER
2,2-DIMETHYL-4-ETHYLHEXANOATE
A solution ofsilver nitrate (2.12 g, 12.5 mmol. in 10
ml. of water) was added to a solution of sodium 2,2-
dimethyl-4-ethythexanoate (prepared in situ by mixing
2.5 ml. of SN. NaOH and 2.15 g of 2,2-dimethyl-4-ethyl-
hexanoic acid in 30 ml. of water). A white precipitate
formed immediately. The mixture wasleft stirring at
room temperature for one hour (protected from light)
mn
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which was separated out byfiltration, washed repeat-
edly with water and dried under vacuum. Yield (90%).
EXAMPLE5
CIS-BIS-NEOHEXANOATO
(TRANS-R,R-1,2-DACH) PLATINUM(II). H:0
Complex #1, cis-bis-Neohexanoato (trans-R.R-1,2-
DACH) platinum (II). H20, was synthesized according
to synthetic route #2 using neohexanoic acid and trans-
R,R-1,2-diaminocyclohexane (DACH). The general
structure of cis-bis-Neohexanoato (trans-R,R-1,2-
DACH)platinum (ID)is as follows:
CHa7
O~C—C—CH2CHa
NH?\ CH;
Pr/ CH;
NH? /O—-C~C~CH2CH3
Oo CH3
Elemental analysis of cis-bis-Neohexanoato (trans-R,R-
1,2-DACH) platinum (II) showed respective percent-
ages for C: H; and N of 38.70%; 6.92%: and 4.91%; as
compared to the calculated percentages of 38.78%;
6.82%; and 5.03%.
EXAMPLE6
CIS-BIS-NEOHEPTANOATO
(TRANS-DL-1,2-DACH) PLATINUM(II)
Complex #2. cis-bis-Neoheptanoato (trans-DL-1,2-
> DACH) platinum (IJ) was synthesized according to
synthetic route #3 using neoheptanoic acid and trans-
DL-1,2 diaminocyclohexane (DACH). The general
structure of cis-bis-Neoheptanoato (trans-DL-1,2-
DACH)platinum (II) is as follows:
ORtofO—-C—C—-RNH2 IR
PL
RNH? |O—-C—C—R’4oO
wherein R.R’ and R”are each methyl, ethyl, propyl or
isopropyl and together have five carbon atoms. Ele-
mental analysis of cis-bis-Neoheptanoato (trans-DL-1,2-
DACH)platinum (II) showed respective percentages
for C; H: and N of 42.03%; 6.86%; and 4.82%; as com-
pared to the calculated percentages of 42.33%; 7.03%;
and 4.94%.
EXAMPLE7
CIS-BIS-NEONONANOATO
(TRANS-DL-1,2-DACH) PLATINUM (II
Complex #3, cis-bis-Neononanoato (trans-DL-1,2-
DACH)platinum (II) was synthesized according to
synthetic route #3, using neononanoic acid and trans-
DL-1,2-diaminocyclohexane (DACH). The general
structure of cis-bis-Neononanoato (trans-DL-1,2-
DACH)platinum (II)is as follows:
5,117,022
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oRWoO—C~—CH—RNH? |\ R
Pr/ R
NH2 tO—-C~C—RoloO
wherein R.R’ and R” are each methyl. ethyl. propyl or
isopropyl! and together have seven carbon atoms. Ele-
mental analysis of cis-bis-Neononanoato (trans-DL-1,2-
DACH)platinum (II) showed respective percentages
for C: H: and N of 45.99%; 7.69%. and 4.36%: as com-
pared to the calculated percentages of 46.23%; 7.70%;
and 4.49%.
EXAMPLE8
CIS-BIS-LAURATO (TRANS-DL-1,2-DACH)
PLATINUM(ID
Complex #4. cis-bis-Laurato (trans-DL-1.2-DACH)
platinum (11) was synthesized according to synthetic ,
route #3 using lauric acid and trans-DL-1.2-diaminocy-
clohexane (DACH). The genera] structure of cis-bis-
Laurato (trans-DL-1.2-DACH) platinum (II) is as fol-
lows:
oO
NH2 omticHacH:
Pr
NH2 OmFICH2NOCH
QO
Elemental analysis of cis-bis-Laurato (trans-DL-1.2-
DACH) platinum (I]) showed respective percentages
for C: H: and N of 50.40%: 8.93%. and 3.78%; as com-
pared to the calculated percentages of 50.93%: 8.49%:
and 3.96%.
EXAMPLE9
CIS-BIS-MYRISTATO (TRANS-DL-1,2-DACH)
PLATINUM(II)
Complex #5,  cis-bis-Myristato  (trans-DL-1,2-
DACH)platinum (II) was synthesized according to
synthetic route #3 using myristic acid and trans-DL-
1,2-diaminocyclohexane (DACH). The general struc-
ture of cis-bis-Myristato (trans-DL-1,2-DACH)plati-
num (II) is as follows:
llNH O—C(CH2)12CH3
\OTFICACHS
oO
Elemental analysis of cis-bis-Myristato (trans-DL-1,2-
DACH)platinum (II) showed respective percentages
for C; H; and N of 53.24%; 9.10%; and 3.45%; as com-
pared to the calculated percentages of 53.47%; 8.91%;
and 3.67%.
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EXAMPLE10
CIS-BIS-NEOHEXANOATO[1.1-BIS
(AMINOMETHYL)CYCLOHEXANE]
PLATINUM(ID
Complex #6,  cis-bis-Neohexanoato  [1,1-bis
(aminomethyl)cyclohexane] platinum (II) was synthe-
sized according to synthetic route #4 using neohex-
anoic acid and 1,1!-bis (aminomethy])cyclohexane. The
general structure of cis-bis-Neohexanoato [1,1-bis
(aminomethy])cyclohexane] platinum (II) is as follows:
CH;ll 7O—C—C—CH2CHCH2NH> CH3\/
Pi
CH2NH?2
Elemental analysis of cis-bis-Neohexanoato [1,1-bis
(aminomethy)cyclohexane] platinum (II) showed re-
spective percentages for C: H: and N of 42.31%; 7.06%;
and 4.90%: as compared to the calculated percentages
of 42.33%; 7.05%, and 4.94%.
EXAMPLE11
CIS-BIS-NEODECANOATO[1.1-BIS
(AMINOMETHYL)CYCLOHEXANE}]
PLATINUM(ID
Complex #7,  cis-bis-Neodecanoato __[I,1-bis
(aminomethy)cyclohexane] platinum (II) was synthe-
sized according to synthetic route #4 using neodeca-
noic acid and 1,1-bis (aminomethyl) cyclohexane. The
general structure of cis-bis-Neodecanoato [1,1-bis
(aminomethy])cyclohexane] platinum (IJ) is as follows:
wherein R,R‘ and R"are each methyl, ethyl, propyl or
isopropy] and together have eight carbon atoms.
A solution of potassium iodide (13.3 g, 0.08 mol.) in
30 ml.of potassium tetrachloroplatinate (II) (4.152 g, 10
mmol.) in 300 ml. of water to give a dark brown solu-
tion. To this solution a mixture of 1,1-bis(aminomethy])
cyclohexane dihydrochloride (2.15, 10 mmol.) and so-
dium hydroxide (0.8 g, 20 mmol.) in 30 ml. of water was
added dropwise. A light yellow ppt. formed immedi-
ately. The mixture wasleft stirring at room temperature
for one hourandthefinal product was separated out by
filtration, washed with 3 x 50 ml. of water and dried
under vacuum to give 4.43 g (75%). Cis-diiodo [1,1-bis-
(aminomethyl)cyclohexane] platinum (II) (0.9847 g, 1.6
mmol.) was suspended in 150 ml. of CHC! and (0.9296
g, 3.35 mmol.) of silver neodecanoate in 50 ml. of
CHCl; was added dropwise. A clear yellowsolution
was formed immediately and the reaction mixture was
left stirring at room temperature for twenty hours (pro-
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tected from light). Silver iodide was separated out by
filtration and the solvent of the filtrate was evaporated
to dryness to give a Jight yellow product. The final
product wasrecrystallized from acetone to give white
crystals. (Yield 79%).
Elemental analysis of cis-bis-Neodecanoato [1.1-bis
(aminomethyl)cyclohexane] platinum (11) showed re-
spective percentages for C; H: and N of 49.58%; 8.02%:
and 4.09%: as compared to the calculated percentages
of 49.48%; 8.25%; and 4.12%.
Other complexesof the invention,i.e. cis-bis-neohex-
anoato [1,1-bis(aminomethyl)cyclohexane] platinum
(II, cis-bis-neoheptanoato —[1,1-bis(aminomethyl)cy-
clohexane] platinum (II), cis-bis-neopentanoato[1,1-bis-
(aminomethy})cyclohexane] platinum (11), and cis-bis-
neononanoato[1,1-bis(aminomethyl)cyclohexane] plati-
num (IF) were prepared in an analogous mannerto the
above mentioned method using stoichiometric amounts
of (ca/1 mmole) diiodo[1,1-bis(aminomethyl)cyclohex-
ane] platinum (II), and the respective silver salts of the
neo-acids i.e. neohexanoic, neoheptanoic, neopentanoic
and neononanoic acid.
EXAMPLE12
. CIS-BIS-NEOHEPTANOATO
(TRANS-R.R-1,2-DIAMINOCYCLOHEXANE)
PLATINUM(II)
Complex #8, cis-bis-Neoheptanoato (trans-R.R-1,2-
DACH) platinum (II) was synthesized according to the
procedure of synthetic route #4 using neoheptanoic
acid and trans-R.R-1,2-diaminocyclohexane (DACH).
The general structure of cis-bis-Neoheptanoato (trans-
R.R-1!,2-DACH) platinum (II) is as follows:
ORloiO-C—C—RNH? J tR
Pr\ RNH: |O-C—C—R
wherein R.R’ and R”are each methyl, ethyl. propyl or
isopropyl and together have five carbon atoms. Ele-
mental analysis of cis-bis-Neoheptanoato (trans-R.R-
1,2-DACH)platinum (II) showed respective percent-
ages for C; H: and N of 41.43%: 6.92%: and 4.84%; as
compared to the calculated percentages of 41.66%;
7.12%; and 4.86%.
Sulfato  (trans-R,R-1,2-diaminocyclohexane) _plati-
num (IJ) (0.423 g, 1 mmol.) in 20 ml. of water was mixed
with a solution of barium neoheptanoate (prepared in
situ by mixing 0.32 g of Ba(OH)2 . 8 H20 in 50 ml. of
water and 0.26 g of neoheptanoic acid in 20 ml. of etha-
nol). A white precipitate formed immediately. The mix-
ture wasleft stirring for three days at room temperature
and the final product was extracted in chloroform and
was dried over anhydrous magnesium sulfate. The mag-
nesium sulfate was separated by filtration, and the fil-
trate was evaporated to dryness to give a light yellow
product which waspurified from acetone. Yield (70%).
Other complexesof the invention,i.e. cis-bis-neohep-
tanonto (trans-RR,SS-1,2-DACH)platinum (1D),cis-bis-
neononanoato (trans-RR,SS-1,2-DACH)platinum (II)
cisbis-laurato (trans-RR,SS-1,2-DACH) platinum (IN),
cis-bis-myristato (trans-RR,SS-1,2-DACH) platinum
(Il) and cis-bis-2-propylpentanoato (trans-RR,SS-1,2-
a
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DACH)platinum (11) were prepared in an analogous
mannerto the above mentioned method using stoichio-
metric amounts of (ca/] mmole) sulfato (trans-RR.SS-
1,2-DACH)platinum and the respective barium salts of
neoheptanoic, neohexanoic, lauric, myristic and 2-
propylpentanoic acid.
EXAMPLE13
CIS-BIS-NEOHEPTANOATO[1.1-BIS
(AMINOMETHYL)CYCLOHEXANE]
PLATINUM(II)
Complex #9, -cis-bis-Neoheptanoato
—
[1,1-bis
(aminomethyl)cyclohexane] platinum (II) was synthe-
sized according to synthetic route #4 using neohep-
tanoic acid and 1,1-bis (aminomethyl)cyclohexane. The
general structure of cis-bis-Neoheptanoato [1,1-bis
(aminomethyl)cyclohexane] platinum (II) is as follows:
CH2NH>
CH2NH?
wherein R.R' and R"are each methyl. ethyl, propyl or
isopropyl and together have five carbon atoms. Ele-
mental analysis of cis-bis-Neoheptanoato  [1,1-bis
(aminomethyl)cyclohexane]platinum (II) showed re-
spective percentages for C: H; and N of 43.98%; 7.91%;
and 4.18%: as compared to the calculated percentages
of 44.37%: 7.39%; and 4.70%.
EXAMPLE 14
CIS-BIS-2,2-DIMETHYLOCTANOATO
(TRANS-R,R-1.2-DACH) PLATINUM (ID)
Complex #10, cis-bis-2,2-dimethyloctanoato (trans-
R,R-1,2-DACH)platinum (II) was synthesized accord-
ing to synthetic route #2 using bis-2,2-dimethyloctanoic
acid and trans-R,R-1,2-diaminocyclohexane (DACH).
The general structure of cis-bis-2.2-dimethyloctanoato
(trans-R,R-1,2-DACH) platinum (1]) is as follows:
O CH:
O—-C—C~(CH2)s—CH3
NH2 CH3
Pr7 \ .
OTEFHSCH
CH3
NH?
O CH;
Elemental analysis of cis-bis-2,2-dimethyloctanoato
(trans-R,R-1,2-DACH)platinum (II) showed respective
percentages for C; H; and N of 47.22%; 7.26%; and
3.949%; as compared to the calculated percentages of
47.92%; 7.99%; and 4.30%.
Sulfato (trans-R,R-1,2-diaminocyclohexane) plati-
num (II) (0.84 g, 2 mmol.) in 25 ml. of water was added
to a solution of sodium 2,2-dimethyloctanoate (prepared
in situ by mixing 0.8 ml. of 5N NaOH and 0.688 g (4
mmol.) of 2,2-dimethyloctanoic acid in 10 ml. of ethanol
and 50 ml. of water). The mixture wasleft stirring for
5,117,022
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two hours and the resulting gummy material was ex-
tracted in chloroform and was dried over anhydrous
magnesium sulfate. The magnesium sulfate was sepa-
rated byfiltration and the filtrate was evaporated to
dryness to give a light yellow product which was puri-
fied from acetone. Yield (77%).
EXAMPLE 15
CIS-BIS-NEONONANOATO
(TRANS-R.R-1,2-DACH) PLATINUM(II)
Complex #11, cis-bis-Neononanoato (trans-R,R-1,2-
DACH)platinum (II) was synthesized according to
synthetic route #1 using neononanoic acid and trans-
R.R-1,2-diaminocyclohexane (DACH). The general
structure of cis-bis-Neononanoato §(trans-R,R-1,2-
DACH)platinum (IJ) is as follows:
O—C—C—R’todO R"
wherein R.R’ and R” are each methyl. ethyl. propyl] or
isopropyl and together have seven carbon atoms. Ele-
mental analysis of cis-bis-Neononanoato (trans-R.R-1,1-
DACH) platinum (ID) showed respective percentages
for C: H; and N of 45.40%; 8.48%: and 4.5%: as com-
pared to the calculated percentages of 46.22%; 4.70%;
and 4.49%.
EXAMPLE 16
CIS-BIS-NEOHEPTANOATO
(ETHYLENEDIAMINE) PLATINUM(ID
Complex #12. cis-bis-Neoheptanoato (ethylenedi-
amine) platinum (H) was synthesized according to syn-
thetic route #1 using neoheptanoic acid and ethylenedi-
amine. The general structure of cis-bis-Neoheptanoato
(ethylenediamine) platinum (H) is as follows:
wherein R,R’ and R”are each methyl, ethyl, propyl or
isopropy! and together have five carbon atoms. Ele-
mental analysis of cis-bis-Neoheptanoato (ethylenedi-
amine) platinum (IJ) showed respective percentagesfor
C: H; and N of 39.96%; 6.67%; and 5.24%; as compared
to the calculated percentages of 37.43%; 6.33%; and
5.46%.
EXAMPLE17
CIS-BIS-NEOPENTANOATO[1,1-BIS
(AMINOMETHYL)CYCLOHEXANE]
PLATINUM(ID
Complex #13,  cis-bis-Neopentanoato  [1,1-bis
(aminomethyl)cyclohexane) platinum (I1) was synthe-
an
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sized according to synthetic route #4 using neopen-
tanoic acid and 1,1-bis (aminomethyl)cyclohexane. The
general structure of cis-bis-Neopentanoato [1.1-bis
(aminomethyl)cyclohexane] platinum (ID) is as follows:
O CH;to
OTeeCHS
CH:NH2?2 CH;7PtoN CH;CH2NH2 one
O CH3
Elemental analysis of cis-bis-Neopentanoato [1,1-bis
(aminomethyl)cyclohexane] platinum (II) showed re-
spective percentages for C: H; and N of 38.59%; 6.04%;
and 4.54%; as compared to the calculated percentages
of 40.07%: 6.68%; and 5.19%.
EXAMPLE 18
CIS-BIS-NEONONANOATO[1.1-BIS
(AMINOMETHYL)CYCLOHEXANE]
PLATINUM (ID
Complex #14, [1.1-bis
(aminomethyl)cyclohexane] platinum (II) was synthe-
sized according to synthetic route #4 using neonona-
noic acid and 1,1-bis (aminomethyl)cyclohexane. The
general structure of cis-bis-Neononanoato [1,1-bis
(aminomethy])cyclohexane] platinum (II) is as follows:
cis-bis-Neononanoato
CH:NH2/
CHaNHe” \ ;
wherein R,R' and R” are each methyl, ethyl, propy! or
isopropyl and together have seven carbon atoms. Ele-
mental analysis of cis-bis-Neononanoato  [1,1-bis
(aminomethyl])cyclohexane] platinum (IJ) showed re-
spective percentages for C; H; and N of 47.43%; 7.14%;
and 3.90%; as comparedto the calculated percentages
of 47.92%; 7.99%; and 4.30%.
EXAMPLE19
C1S-BIS-2-ETHYLHEXANOATO
(TRANS-DL-1,2-DACH) PLATINUM(II) . H20
Complex #15, cis-bis-2-ethylhexanoato (trans-DL-
1,2-DACH)platinum (II) H2O was synthesized accord-
ing to synthetic route #2 using 2-ethyl hexanoic acid
and trans-DL-1,2-diaminocyclohexane (DACH). The
general structure of cis-bis-2-ethylhexanoato (trans-DL-
1,2-DACH)platinum (ID) is as follows:
5,117,02217
oO CiHs
OmC—C—(CH23CHS\H
H
NH2 /\ Pt7NH2 /
OmC—C—(CH2)3CHa
C3Hs
Elemental analysis of cis-bis-2-ethylhexanoato (trans-
DL-1!,2-DACH) platinum (II) showed respective per-
centages for C; H; and N of 43.29%; 7.74%; and 4.31%:
as compared to the calculated percentages of 43.21%;
7.53%; and 4.58%.
EXAMPLE20
CIS-BIS-2-ETHYLBUTYRATO
(TRANS-DL-1,2-DACH) PLATINUM (II). H20
Complex #16, cis-bis-2-ethylbutyrato (trans-DL-1.2-
DACH)platinum (11) H2O0 was synthesized according
to synthetic route #2 using 2-ethylbutyric acid and
trans-DL-diaminocyclohexane (DACH). The general
Structure of  cis-bis-2-ethylbutyrato (trans-DL-1,2-
DACH)platinum (II) is as follows:
oO CH2CH:
O—C—C—H
NH2\ CH2CH:
Pt7 CH:CH3;NH?
ome
Oo CH>CH:;
Elemental analysis of cis-bis-2-ethylbutyrato (trans-DL-
1.2-DACH) platinum (II) showed respective percent-
ages for C: H; and N of 38.28%: 6.56%: and 4.71%: as
compared to the calculated percentages of 38.78%,
6.82%. and 5.03%.
EXAMPLE21
CIS-BIS-2-PROPYLPENTANOATO
(TRANS-DL-1,2-DACH) PLATINUM(IF) .H20
Complex #17, cis-bis-propylpentanoato (trans-DL-
1.2-DACH)platinum (II). H 0 was synthesized accord-
ing to synthetic route #3 using 2-propylpentanoic acid
and trans-DL-1,2-diaminocyclohexane (DACH). The
general structure of cis-bis-2-propylpentanoato (trans-
DL-1.2-DACH)platinum (ID)is as follows:
0 CH2CH2CHa
O—-C—C—H
NH2\ CH2CH2CH3
Pi7 CH2CH2CH3
NH2 o-e—crH
Oo CH2CH2CH;
Elemental analysis of cis-bis-2-propylpentanoato (trans-
b 1,2-DACH)platinum (11) showed respective percent-
ages for C; H; and N of 43.11%; 7.10%; and 4.59%; as
compared to the calculated percentages of 43.71%;
7.45%; and 4.64%.
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EXAMPLE22
CIS-BIS-2-METHYL-2-ETHYLHEPTANOATO
(TRANS-R.R-1,.2-DACH) PLATINUM(I)
Complex #18,  cis-bis-2-methyl-2-ethylheptanoato
(trans-R.R-1.2-DACH) platinum (If) was synthesized
according to synthetic route #2 using 2-methyl-2-ehtyl-
heptanoic acid and diaminocyclohexane (DACH). The
general structure of cis-bis-2-methy]-2-ethylheptanoato
(trans-R,R-1 ,2-DACH)platinum (IH) is as follows:
CH3
IO—-C—C—(CH2)sCHaaNNH2™~\ / CoHs
Pr
CHNHS” \ 3
O—C—C—(CH2)sCH3oNCoHs
Elemental analysis of cis-bis-2-methy]-2-ethylhep-
tanoato (trans-R,.R-1,2-DACH) platinum (II) showed
respective percentages for C: H: and N of 43.75%;
7.69%: and 4.23%: as compared to the calculated per-
centages of 47.92%; 7.99%: and 4.30%.
EXAMPLE 23
CIS-BIS-2,2-DIETHYLHEXANOATO
(TRANS-R.R-1,2-DACH) PLATINUM (II)
Complex #19, cis-bis-2,2-diethyJhexanoato (trans-
R,R-1,2-DACH)platinum (ID was synthesized accord-
ing to synthetic route #2 using 2,2-diethylhexanoic acid
and trans-R,R-1,2-diaminocyclohexane (DACH). The
general structure ofcis-bis-2,2-diethylhexanoato (trans-
R.R-1,2-DACH)platinum (IP) is as follows:
Oo CoHsIfO—CC(CH2)aCH3\C2Hs
CoHs
O-C—C—(CH2)3CH3loNoO CoHs
Elemental analysis of cis-bis-2,2-diethylhexanoato
(trans-R,R-1,2-DACH)platinum (1) showed respective ‘
percentages for C; H; and N of 47.08%; 7.38%; and
4.05%; as compared to the calculated percentages of
47.92%; 7.99%; and 4.30%.
EXAMPLE24
CIS-BIS-2,2-DIMETHYL-4-ETHYLHEXANOATO
(TRANS-R,R-1,2-DACH) PLATINUM (I)
Complex #20, cis-bis-2,2-dimethyl-4-ethylhexanoato
(trans-R,R-1,2-DACH)platinum (II) was synthesized
according to synthetic route #2 using 2,2-dimethyl-4-
ethylhexanoic acid and trans-R,R-1,2-diaminocyclohex-
ane (DACH). The general structure of cis-bis-2,2-
dimethy]-4-ethylhexanoato (trans-R,R-1,2-DACH)
platinum (II) is as follows:
5,117,022
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Oo CH; C3Hs
It 7O—C—C—CH:~CHNH2 J NN\ CH CoHs
Pr/ \ CH; C2Hs
NH?
O—-C—-C—CHi—CH
CH; CoHs
Diiodo (trans-R.R-1,2-diaminocyclohexane) platinum
(1) (0.84 g. 1.5 mmol.) was addedasa solid to a solution
of silver 2,2-dimethyl-4-ethylhexanoate (0.83 g. 3
mmol.) in 150 ml of chloroform. The mixture was kept
on stirring overnight at room temperature (protected
from light). Silver iodide was separated byfiltration and
the filtrate was evaporated to dryness to give a light
yellow product which was purified from acetone to
give a white product. Yield (73%).
Elemental analysis of cis-bis-2.2-dimethyl-4-ethylhex-
anoato (trans-R.R-1.2-DACH) platinum (II) showed
respective percentages for C, H; and N of 47.63%;
7.70%: and 4.08%, as compared to the calculated per-
centages of 47.92%; 7.99%; and 4.30%.
Other complexes of the invention,i.e. cis-bis-neohep-
tanoato (trans-R.R-1.2-DACH) platinum (II). cis-bis-
neonanoato (trans-R.R-1.2-DACH) platinum (II), cis-
bis-2.2,4.4-tetramethylpentanoato (trans-R,R-1.2-
DACH) platinum (II) and cis-bis-neoheptanoato (ethy!-
enediamine) platinum (Il) were prepared in an analo-
gous manner to the above mentioned method using
stoichiometric amounts of appropriate diamine diiodo-
platinum (11), and silver salt of respective neo acid.
EXAMPLE 25
CIS-BIS-2.2-DIETHYL-4-METHYLPEN-
TANOATO (TRANS-R.R-1.2-DACH) PLATINUM
(i)
Complex #21, cis-bis-2,2-diethy!-4-methylpentanoato
(trans-R.R-1.2-DACH) platinum (II) was synthesized
according to synthetic route #2 using 2,2-diethyl-4-
methylpentanoic acid and trans-R.R-],2-diaminocy-
clohexane (DACH). The general structure of cis-bis-
2,2-diethy]-4-methylpentanoato (trans-R,R-1,2-DACH)
platinum (II) is as follows:
t CoHs CH;
O—-C—C—CH2—-CHNH2 LS \~\ C2Hs CH3
Pi\ C2Hs CH3
NH2 O—-C—C-—-CH:—-CHloNCoHs CH3
Elemental analysis of cis-bis-2,2-diethy]l-4-methylpen-
tanoato (trans-R,R-1,2-DACH)platinum (IY) showed
respective percentages for C; H:; and N of 47.64%;
7.75%; and 4.16%; as compared to the calculated per-
centages of 47.92%; 7.999%; and 4.30%.
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EXAMPLE 26
CIS-BIS-2,2-DIMETHYLOCTANOATO
(S.S-1,.2-DIAMINOCYCLOHEXANE) PLATINUM
(i)
Complex #22, cis-bis-2,2-dimethyloctanoato (trans-
§.S-1.2-DACH) platinum (II) was synthesized accord-
ing to synthetic route #2 using 2.2-dimethyloctanoic
acid and trans-S,S-1,2-diaminocyclohexane (DACH).
The general structure of cis-bis-2,2-dimethyloctanoato
(trans-S,S-1,2-DACH)platinum (II) is as follows:
t CH3
O—-C—C—(CH2)sCH3
NH2 ‘\\ CH;
Pr7 CH3NH2 /
OMETCSCHSCH
CH;
Elemental analysis of cis-bis-2,2-dimethyloctanoato
(trans-S,S-1,.2-DACH) platinum (II) showed respective
percentages for C; H: and N of 47.63%: 8.05%; and
4.15%; as compared to the calculated percentages of
47.92%: 7.99%: and 4.30%.
In summary, complexes of the invention synthesized
by this general procedure include, i.e. cis-bis-neonep-
tanoato (trans-R,R-1,2-DACH) platinum (II), cis-bis-
*° dimethyloctanoato (trans-R,R-1,2-DACH) platinum
(ID. cis-bis-2-ethylhexanoato (trans,RR,SS-1,2-DACH)
platinum (ID, cis-bis-2-ethylbutyrato (trans-R,R-1,2-
DACH) platinum (II).  cis-bis-2-metyl-2-ethylhep-
tanoato (trans-R,R-1,2-DACH) platinum (II), cis-bis-
2,2-diethylhexanoato (trans-R,R-1,2-DACH) platinum
(II). cis-bis-2.2-dimethyl-4-ethylhexanoato (trans-R,R-
1,2-DACH)platinum (II), cis-bis-2.2-diethy]-4-methyl-
pentanoato (trans-R.R-1,2-DACH) platinum (II), cis-
bis-2,2-dimethyloctanoato (trans-S,S-1,2-DACH)plati-
num (II), cis-bis-2-methyl-2-ethylheptanoato (trans-S,S-
1,2-DACH)platinum (II), and cis-bis-2.2-diethylhex-
anoato (trans-S,S-1,2-DACH) platinum (II) were pre-
pared in an analogous mannerto the above mentioned
method using stoichiometric amounts (ca/mmole) of
appropriate sulfato (DACH)platinum (II) and sodium
salt of appropriate neo-acid..
EXAMPLE27
CIS-BIS-2-METHYL-2-ETHYLHEPTANOATO
(TRANS-S,S-1,2-DACH) PLATINUM(IT)
Complex #23,  cis-bis-2-methy]-2-ethylheptanoato
(trans-S,S-1,2-DACH) platinum (II) was synthesized
according to synthetic route #2 using 2-methy]-2-ethyl-
heptanoic acid and _trans-S,S-I,2-diaminocyclohexane
(DACH). The general structure of cis-bis-2-methyl-2-
ethylheptanoato (trans-S,S-I,2-DACH)platinum (II) is
as follows:
5,117,02221
° CH;li 7O—C~—C—(CH2)3CH3
MO
PtoN
inCoHs
CHs
NH2
OBSCHEER
Hs 10
Elemental analysis of cis-bis-2-methyl-2-ethylhep-
tanoato (trans-S.S-1.2-DACH) platinum (II) showed
respective percentages for C; H; and N of 47.77%:
8.01%; and 4.15%: as compared to the calculated per-
centages of 47.92%; 7.99%; and 4.30%.
EXAMPLE28
CIS-BIS-2,2-DIETHYLHEXANOATO
(TRANS-S,S-1,2-DACH) PLATINUM(II)
Complex #24, cis-bis-2.2-diethylhexanoato (trans-
§,S-1,2-DACH) platinum (II) was synthesized accord-
ing to synthetic route #2 using 2.2-diethylhexanoic acid
and trans-S.§-1,2-diaminocyclohexane (DACH). The
general structure ofcis-bis-2.2-diethylhexanoato (trans-
§.S8-1,.2-DACH)platinum (1]) is as follows:
Oo C3Hslf
O—C—C—CH2CH2CH2CH: «30
CH2™H2APtoN
CrH«
CoHsCH2NH>
O—C—C—CH:2CH:CH2CH:oNa CaHs
Elemental analysis of cis-bis-2,.2-diethylhexanoato
(trans-S,S-1,2-DACH)platinum (II) showed respective
percentages for C; H; and N of 47.76%: 7.87%: and
4.22%; as compared to the calculated percentages of
47.92%; 7.99%: and 4.30%.
EXAMPLE 29
CIS-BIS-2,2-DIETHYL-4-METHYLPEN-
TANOATO (TRANS-S,S-1,2-DACH) PLATINUM
qy)
Complex #25, cis-bis-2,2-diethyl-4-methylpentanoato
(trans-S,S-1,2-DACH) platinum (IF) was synthesized
according to synthetic route #1 using 2,2-diethyl-4-
methylpentanoic acid and trans-S.S-1,2-diaminocy-
clohexane (DACH). The general structure of cis-bis-
2,2-diethyl-4-methylpentanoato (trans-S,S-1,2-DACH)
platinum (II) is as follows:
40
35
iO—C—C=—CH)—CH\CH;
Co2Hs CH;
NH?\ / . CzHs
Pi
C3Hs
O—-C—C—CH;}—CHtoN
CH3
NHz
C2Hs CH3
65
Elemental analysis of cis-bis-2,2-diethyl-4-methylpen-
tanoato (trans-S,S-1,2-DACH) platinum (11) showed
respective percentages for C; H; and N of 47.10%;
22
8.15%: and 4.15%: as comparedto the calculated per-
centages of 47.926: 7.99%: and 4.30%.
EXAMPLE30
CIS-BIS-2,2.4.4-TETRAMETHYLPENTANOATO
(TRANS-R,R-1,2-DACH) PLATINUM (ID
Complex #26, cis-bis-2,.2.4,4-tetramethylpentanoato
(trans-R.R-1.2-DACH) platinum (I]) was synthesized
according to synthetic route #1 using 2.2-4,4-tetrame-
thylpentanoic acid and trans-R,R-1,2-diaminocyclohex-
ane (DACH). The general structure of cis-bis-2,2,4,4-
tetramethylpentanoato (trans-R,R-1,2-DACH) _plati-
num (II) is as follows:
CH3oO CH3il 4 7O~C—-C—CH:"C—CHi\ \CH3 CH3NH?\,7t7 CH3 CHxa’ \ 4 ,O-C—C—CHi-CCH
oN \oO CH: CH3
Elemental analysis of cis-bis-2.2,4.4-tetramethylpen-
tanoato (trans-R.R-1.2-DACH) platinum (IJ) showed
respective percentages for C: H: and N of 45.93%;
7.83%; and 4.47%; as compared to the calculated per-
centages of 46.22%; 7.70%; and 4.49%.
EXAMPLE31
CIS-BIS-NEODECANOATO
(cis-1,2-DIAMINOCYCLOHEXANE) PLATINUM
(It)
Complex #27.  cis-bis-neodecanoato —(cis-1,2-
diaminocyclohexane) platinum (II) was synthesized
according to synthetic route #1 using an isomeric mix-
ture of neodecanoic acids and cis-1,2-diaminocyclohex-
ane (DACH). The general structure of cis-bis-
Neodecanoato (cis-1.2-DACH) platinum (IJ)is as fol-
lows:
where R,R' and R” are each methyl, ethyl, propyl or
isopropyl and together have eight carbon atoms. Ele-
mental analysis of cis-bis-Neodecanoato (cis-1,2-
DACH)platinum (II) showed respective percentages
for-C; H; and N of 46.86%; 8.13%; and 4.27%; as com-
pared to the calculated percentages of 46.23%; 7.70%;
and 4.49%.
EXAMPLE32
THE PREPARATION OF LIPOSOMAL
PREPARATIONS CONTAINING
HYDROPHOBIC PLATINUM COMPLEXES
Multilamellar lipid vesicles (MLV)or liposomes con-
taining incorporated platinum complexes of the above
descriptions were prepared as previously described for
5,117,02223
other compounds (Lopez-Berestein et al. (4)(1984) Clin.
Exp. Metastasis V 2 pp 127-137 and Lopez-Berestein et
al. (1983) J. Inf. Dis. V 147 pp 937-945). In brief, chlo-
roform solutions of lipids (at the desired molar ratio)
and platinum complex were mixed at a lipid-PT ratio of
15:1 and the chloroform was evaporated in a rotary
evaporator (Buchi, Brinkmann Instruments, Westbury,
N.Y.). The dried lipid film obtained, containing plati-
num complex, was then dispersed with an aqueoussolu-
tion (0.9% NaCl in water) by vigorous handshaking.
The suspension was subsequently centrifuged at
30,000xg for 45 minutes, the supernatant was dis-
carded, and the pellet containing platinum complex was
resuspended in 0.9% NaCl solution.
MLYor liposomes containing platinum complexes
mayalso be prepared from a lyophilized powder con-
taining lipid and platinum compound. The lipid and
platinum compound are dissolved in the hydrophobic
solvent tertiary butanol (M.P. 26° C.) at the ratios de-
scribed above. The solution is freeze-dried and a white
powder obtained. MLVcontaining the platinum com-
pound are formed upon the addition of 0.9% NaCl
solution in water to the lyophilized powder with mild
shaking by hand.
An alternative method for the preparation of lipo-
somes containing different platinum complexes has been
developed as follows:
1. The drug andthe lipids in chloroform are mixedat
an adequate drug:lipid weight ratio.
2. The chloroform is evaporated in a rotary evapora-
tor.
3. The dry hpid film is dissolved in t-butanol.
4+. The solution of drug and lipids in t-butanolis ly-
ophilized overnight. A white, flaky powder is ob-
tained.
5. Multilamellar liposomes containing platinum com-
plexes are formed by adding an aqueoussolution to
the dry powder and mild handshaking for 1-20
minutes. depending on the drug being used. En-
trapment and size distribution are similar to those
obtained with other methodsof liposome prepara-
tion described herein.
EXAMPLE33
IN VIVO ANTITUMORACTIVITY OF
LIPOSOMALLY ENCAPSULATED PLATINUM
COMPLEXES AGAINST L1210 MOUSE
LEUKEMIA
The in vivo antitumoractivity of liposomal encapsu-
lated platinum complexes in liposomes
DMPC:DMPG7:3 wastested in an L1210-BDF; mouse
model. BDF mice were purchased from Charles River
(Wilmington, Mass.). Groups of 6-8 mice weighing
18-22 gm were inoculated ip with 1 x 10 L1210 leuke-
mia cells on day 0. L1210 cells were kept in DBA2 mice
with weekly passages between the different experi-
ments. All liposomal encapsulated platinum complexes
preparations wereinjectedip in volumesof 0.1 to 0.3 ml
24 hoursafter tumor inoculation. The doses of liposo-
mal complexes used were ones that had resulted in a
maximum antitumor activity in previous experiments.
The doses of liposomal! platinum complexes used ranged
from 25 mg/kg to 50 mg/kg (approximate Clinical be-
havior and survival times were monitored until all ani-
mals had died. Results were expressed as % T/C (me-
dian survival time of treated mice/median survival time
of control mice < 100). All preparations tested for anti-
tumoractivity were prepared understerile conditions
5
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on the same dayof the experiment. Theeffect ofa single
ip dose of various PT(II) complexes in liposomes
(DMPC:DMPG 7:3) in the treatment of L1210 leuke-
mia was tested. The T/C forcis platinum at a dose of 10
mg was 175.
The following table show's the optimal dose and T/C
data for certain compoundsofthe present invention.
TABLE2
OPTIMAL DOSE AND ANTITUMOR ACTIVITY
AGAINST IP L1210 LEUKEMIA
 
Liposomal Optimal Dose
preparation me/kg % T/C
! $0 162
2 50 378
3 50 165
4 50 162 -
5 100 162
6 50 172
7 50 200
8 25 175
9 25 225
10 25 228
il 50 > 150
12 50 120
13 50 > 150
14 25 > 150
18 50 > 150
16 28 162
17 50 162
18 25 316
19 28 357
20 50 212
21 28 225
22 25 150
23 50 210
24 50 190
25 50 160
26 50 150
27 25 170
 
EXAMPLE 34
CALCULATION OF ENCAPSULATION
EFFICIENCY(EE)
Elemental platinum (Pt) was determined in the lipo-
some suspension and the pellet by x-ray fluorescence as
previously reported (Seifert et al. (1979) Proc. Amer.
Ass'n. Cancer Res. V 20 p. 168) in the Department of
Analytical Chemistry, the University of Texas medical
School at Houston, Tex. The amount of platinum com-
plex (PT) was determined in the supernatant by ultravi-
olet (UV) spectrophotometryusing a wavelength of 224
nm. The EE wasinitially calculated with the two fol-
lowing formulas:
1. EE=Pt in pellet/total Pt in the initial liposome
suspension
2. EE=Total Pt initially added - Pt in supernatant-
/total Pt initially added
Since the results obtained by these two methods were
highly comparable and the second methodonly requires
Pt determination by UV spectrophotometry, most EE
determinations were calculated with the second
method.
The following Table shows encapsulationefficiencies
for complexes of the present invention.
TABLE2
ENCAPSULATION EFFICIENCY
Liposomal
preparation
 
Encapsulation
%
1 90
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TABLE2-continued
ENCAPSULATION EFFICIENCY
Liposomal
preparation
 
Encapsulation
# %
2 100
3 100
4 100
5 100
6 100
7 100
8 100
9 100
10 100
MW 100
12 100
13 80
14 94
is 94
16 100
17 100
18 100
19 100
20 100
2! 100
22 100
23 100
24 100
28 100
26 $00
27 100
 
Whatis claimedis:
1. A platinum (II) four-coordinate complex having 3
the formula:
/
RimPull}\ Ra
wherein R; is an alkyl diamine or cycloalky] diamine
and R2and R3are each a hydrophobic alkyicarboxylato
containing from five to fourteen carbon atoms.
2. The platinum (11) four-coordinate complex of
claim 1 wherein R; is trans-D,L-1.2-diaminocyclohex-
ane, trans-R,R-1,2-diaminocyclohexane, trans-S,S-1.2-
diaminocyclohexane, cis-1,2-diaminocyclohexane. eth-
ylene diamine or 1,1-bis(aminomethy])cyclohexane.
3. The platinum (II) four-coordinate complex of
claim I wherein R2 and Ra are neohexanoato, neohep-
tanoato, neononanoato, neodecanoato, neooctanoato,
neopentanoateo, 2-ethylhexanoato, 2-ethylbutyrato,
2-propylpropanoato, 2-methyl-2-ethylheptanoato, 2,2-
diethylhexanoato, 2,2-dimethy]-4-ethylhexanoato, 2,2-
diethyl-4-methylpentanoato, 2,2-dimethyloctanoato,
2-methyl-2-ethylheptanoato, 2,2-diethylhexanoato, 2,2-
diethy]-4-methylpentanoato or 2,2,4,4-tetramethylpen-
tanoato.
4. A platinum (I) four-coordinate complex, cis-bis-
neohexanoato (trans-R,R-1,2-DACH) platinum (Id)
H20.
§. A platinum (11) four-coordinate complex, cis-bis-
neoheptanoato (trans-R,R-S,S-1,2-DACH) platinum
(i).
6. A platinum (ID four-coordinate complex, cis-bis-
neononanoato (trans-R,R-S,S-1,2-DACH) platinum
qII).
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7. A platinum (II) four-coordinate complex, cis-bis-
neohexanoato[1,1-bis (aminomethyl)cyclohexane] plat-
inum (II)
8. A platinum (I) four-coordinate complex, cis-bis-
neodecanoato[1,1-bis (aminomethyl)cyclohexane] plat-
inum (II).
9. A platinum (11) four-coordinate complex, cis-bis-
neoheptanoato (trans-R.R-I,2-DACH)platinum (IJ).
10. A platinum (II) four-coordinate complex, cis-bis-
neoheptanoato [I,l-bis (aminomethyl)cyclohexane]
platinum (II).
11. A platinum (11) four-coordinate complex, cis-bis-
2,2-dimethyloctanoato (trans-R,R-1,2-DACH) _plati-
num (II).
12. A platinum (II) four-coordinate complex, cis-bis-
neononanoato (trans-R,R-1,2-DACH)platinum (11).
13. A platinum (11) four-coordinate complex,cis-bis-
neoheptanoato (ethylenediamine) platinum (IJ).
14. A platinum (II) four-coordinate complex, cis-bis-
neopentanoato [1,1-bis (aminomethyl)cyclohexane]
platinum (ID).
15. A platinum (II) four-coordinate complex. cis-bis-
neononanoato[1,1-bis (aminomethyl)cyclohexane] plat-
inum (II).
16. A platinum (IJ) four-coordinate complex. cis-bis-
2-ethy]hexanoato (trans-R,R-S,S-1,2-DACH) platinum
(11) H20.
17. A platinum (IT) four-coordinate complex, cis-bis-
ethylbutyrato (trans-R.R-S.S-1,2-DACH) platinum (II)
H>20.
18. A platinum (11) four-coordinate complex, cis-bis-
propylpentanoato (trans-R,R-S,S-1,2-DACH) platinum
(IH) H20.
19. A platinum (II) four-coordinate complex, cis-bis-
2-methyl-2-ethylheptanoato (trans-R,R-1,2-DACH)
platinum (ID.
20. A platinum (IT) four-coordinate complex, cis-bis-
2.2-diethylhexanoato (trans-R,R-1,2-DACH) platinum
(II). .
21. A platinum (II) four-coordinate complex, cis-bis-
2,2-dimethyl-4-ethylhexanoato (trans-R,R-1,2-DACH)
platinum (II).
22. A platinum (II) four-coordinate complex, cis-bis-
2.2-diethyl-4-methylpentanoato (trans-R.R-1,2-DACH)
platinum (1).
23. A platinum (II) four-coordinate complex,cis-bis-
2,2-dimethyloctanoato (trans-S,S-1,2-DACH)platinum
(II).
24. A platinum (II) four-coordinate complex, cis-bis-
2-methyl-2-ethylheptanoato (trans-S,S-1,2-DACH)
platinum (II).
25. A platinum (ID) four-coordinate complex, cis-bis-
2,2-diethy!lhexanoato (trans-§,S-I,2-DACH) platinum
(II).
26. A platinum (II) four-coordinate complex,cis-bis-
2,2-diethyl-4-methylpentanoato (trans-S,S-1,2-DACH)
platinum (II).
27. A platinum (II) four-coordinate complex, cis-bis-
2,2,4,4-tetramethylpentanoato (trans-R,R-1,2-DACH)
platinum (ID.
28. A platinum (II) four-coordinate complex, cis-bis-
neodecanoato (cis-1,2-diaminocyclohexane platinum
(Id).
* * *x x *
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At column 12, line 64, "CHCl" should be ~-CHC1,--.
At column 13, line 54, "Ba(OH),.8 H,0" should be--Ba (OH) 2° 8 H,0-- .
At column 16, line 60, "PLATINUM (II) .H,O" should be~~PLATINUM (II) *H,O--.  
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It is certified that error appears in the above-indentified patent and that said Letters Patent is hereby
corrected as shown below:
At column 16, line~~platinum (II) -H,o--.
At column 17, line~-PLATINUM (II) -H,0--.
At column 17, line~~platinum (II) -H,o--.
At column 17, line~~PLATINUM (II) -H,0o--.
. At column 17, line--platinum (II) -H,O--.
At column 20, line
64,
20,
22,
46,
49,
42,4-ethylhexanoato" should beethylhexanoato--.
At column 23, lineinserted --LD,)) .-- 63,
“platinum (ITI) H,O" should be
"PLATINUM (IT) -H,O" should be
“platinum (II) H,O" should be
"PLATINUM (II).H,0" should be
"platinum (II).H o" should be
"(II), cis-bis-2,2-dimethyl---(II), cis-bis-2,2~dimethy1-4-
after "(approximate" should be  
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It is certified that error appears in the above-indentified patent and that said Letters Patent is hereby
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At column 24, line 45, "medical" should be --Medical--.
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BRUCE LEHMAN
Antesting Officer Commissioner of Patents and Trademarks
  
